GlassScriptPhysician profile
Clara N Cabrera
NPI 1487851697
$4,120.37
in general payments reported to CMS, 2019-2025
21 companies · $523 in 2025
The $523 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,661 · 2020: $518 · 2021: $550 · 2022: $62.81 · 2023: $504 · 2024: $302 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,327.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,207.51 | 2019-2025 | Arexvy, Nucala, Shingrix |
| Astrazeneca Pharmaceuticals LP | $716.23 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $288.20 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $245.00 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $233.19 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $167.85 | 2019 | |
| Lilly USA, LLC | $165.17 | 2019-2025 | Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $157.41 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $143.20 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $136.99 | 2019 | |
| Mallinckrodt Hospital Products INC. | $116.23 | 2021 | |
| Viiv Healthcare Company | $92.96 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.33 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Takeda Pharmaceuticals U.S.A., INC. | $70.20 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $68.41 | 2024-2025 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $53.69 | 2019-2020 | |
| Astellas Pharma US INC | $48.19 | 2023 | Veozah, Myrbetriq |
| Abbvie INC. | $41.98 | 2023 | Qulipta, Creon, Linzess |
| Janssen Pharmaceuticals, INC | $37.46 | 2019 | |
| Allergan, INC. | $34.25 | 2019 | |
| Kaleo, INC. | $18.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clara Cabrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.